Fumetinib drives performance growth, Shanghai Allist Pharmaceuticals Co., Ltd. expects net profit to increase by over 120% year-on-year in 2024.

① During the reporting period, Shanghai Allist Pharmaceuticals Co., Ltd. achieved revenue of 3.558 billion yuan, a year-on-year increase of 76.29%; net income attributable to shareholders was 1.43 billion yuan, up 121.97% year-on-year, and net income excluding extraordinary items was 1.361 billion yuan, an increase of 124.51% year-on-year; ② The net cash flow reached 1.566 billion yuan, a growth of 132.12% compared to 0.675 billion yuan in the same period last year. Ample funds are beneficial for expanding R&D investment.

cls.cnApr 24 00:28 ET

Yantai China Pet Foods' net profit increased by nearly 70% last year, with an improved proportion of OEMs, but may face the "growing pains" of trade frictions. | Interpretations

① The main markets for Pet Food both domestically and internationally have maintained a certain growth rate, with Yantai China Pet Foods achieving an increase in revenue and Net income last year; ② Industry observers have told the Financial Associated Press that nearly 70% of Yantai China Pet Foods' revenue comes from overseas, and the first quarter was not affected by tariff conflicts, but the second and third quarters may face some "growing pains." The specific impact on the company remains to be seen.

cls.cnApr 23 09:45 ET

Large products' sales volume increased, Yanker Shop Food's net income last year increased by more than 20% year-on-year | Interpretations

① Benefiting from the volume increase of L products and the expansion of all channels, Yanker Shop Food achieved double growth in revenue and Net income in 2024; ② In 2025, the company will intensify the development of new products, continue the all-channel strategy, and focus on the konjac and quail egg categories to gain traction in the Southeast Asian market and explore the Japanese, Korean, and European-American markets.

cls.cnApr 22 09:58 ET

Sunshine Guojian Pharmaceutical: Q1 revenue grew by 16.6%, with several positive developments in the R&D pipeline.

Sunshine Guojian Pharmaceutical's Q1 revenue grew by 16.6%, with multiple positive developments in the R&D pipeline. Summary of key points: Financial performance: Q1 revenue in 2025 was 0.311 billion...

wallstreetcnApr 22 06:43 ET

The "sanitary napkin renovation" incident impacted the factory's commercial performance, Chongqing Baiya Sanitary Products Q1 online revenue growth sharply reduced | Interpretations

① Chongqing Baiya Sanitary Products' Q1 performance continues to grow, but there are drastic changes on the channel side; ② The offline channel suddenly surged, with a year-on-year growth rate of 49%, becoming the growth engine; ③ The previously rapidly developing online channel has stalled, with a year-on-year growth rate dropping to 8.6%, lagging behind the Industry Large Cap.

cls.cnApr 18 10:13 ET

Tariff Fears Pose 'Material Risks' To US And Global Economies, Goldman Sachs CEO Warns

BenzingaApr 14 16:40 ET